Blood and marrow transplantation in elderly acute myeloid leukaemia patients – older certainly is not better
Authors:
- 18 June 2007
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 40 (5) , 405-416
Abstract
Acute myeloid leukaemia in the elderly is a disease with distinct biological properties, commonly associated with leukaemic cell treatment resistance and with an increased number of high-risk features, including concomitant myelodysplasia and poor-risk cytogenetic abnormalities such as monosomy 5 and 7. Complete remission rates after standard induction chemotherapy in patients above age 60 years are less than 50%, with long-term survival rates below 10%. Post-remission stem cell transplant therapies have not been studied extensively. Autologous transplants can result in an acceptable 3-year leukaemia-free survival rate of up to 47%, yet this procedure is applicable only to a small minority of patients. Myeloablative allogeneic transplants similarly show feasibility in selected few patients and in general are very toxic. Non-myeloablative allogeneic transplants are associated with reduced toxicity, but are plagued by an increased relapse rate. The latter strategy appears promising, but must be validated in larger, multi-centre prospective trials, in which outcomes are compared to non-transplant approaches.Keywords
This publication has 60 references indexed in Scilit:
- Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)Bone Marrow Transplantation, 2006
- Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional ConditioningTransplantation and Cellular Therapy, 2005
- Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (≥ 60 years) with active myeloid malignanciesBlood, 2005
- Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageBlood, 2005
- The relationship of patient age to the pathobiology of the clonal myeloid diseasesSeminars in Oncology, 2004
- Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantationBone Marrow Transplantation, 2001
- Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cellsBritish Journal of Haematology, 2000
- Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim reportBone Marrow Transplantation, 1999
- Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot studyBone Marrow Transplantation, 1998
- Population‐Based Age‐ and Sex‐Specific Incidence Rates in the 4 Main Types of LeukaemiaScandinavian Journal of Haematology, 1982